Clinical overview of sorafenib in breast cancer (Q37750770)

22 August 2017

1 reference

title

Clinical overview of sorafenib in breast cancer (English)

1 reference

22 August 2017

1 reference

Alvaro Moreno-Aspitia

series ordinal

1

1 reference

PubMed ID

20465381

22 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

22 August 2017

1 reference

22 August 2017

6

1 reference

22 August 2017

5

1 reference

22 August 2017

655-663

1 reference

Global trends in breast cancer incidence and mortality 1973-1997.

22 August 2017

1 reference

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

Hyperexpression of mitogen-activated protein kinase in human breast cancer

21 January 2018

1 reference

Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions

21 January 2018

1 reference

VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells

21 January 2018

1 reference

Signal transduction pathway targets for anticancer drug discovery

21 January 2018

1 reference

The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia

21 January 2018

1 reference

Kinases: positive and negative regulators of apoptosis.

21 January 2018

1 reference

Signal transduction by receptors with tyrosine kinase activity

21 January 2018

1 reference

The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors

21 January 2018

1 reference

Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human raf-1 protein kinase

21 January 2018

1 reference

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

The biology of VEGF and its receptors

21 January 2018

1 reference

Vascular endothelial growth factor as a target for anticancer therapy

21 January 2018

1 reference

Angiogenesis: update 2005.

21 January 2018

1 reference

Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy

21 January 2018

1 reference

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: Correlation with stage and rate of progression

21 January 2018

1 reference

Pharmacological inhibitors of MAPK pathways.

21 January 2018

1 reference

New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors

21 January 2018

1 reference

New targeted therapies in breast cancer

21 January 2018

1 reference

Inhibition of PI3K and MEK: it is all about combinations and biomarkers

21 January 2018

1 reference

Targeted therapies in breast cancer: established drugs and recent developments

21 January 2018

1 reference

Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists

21 January 2018

1 reference

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

21 January 2018

1 reference

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

21 January 2018

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

BAY 43-9006: preclinical data

21 January 2018

1 reference

The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors

21 January 2018

1 reference

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

21 January 2018

1 reference

BAY 43-9006: early clinical data in patients with advanced solid malignancies

21 January 2018

1 reference

BAY 43-9006 inhibition of oncogenic RET mutants

21 January 2018

1 reference

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

21 January 2018

1 reference

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

21 January 2018

1 reference

Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.

21 January 2018

1 reference

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

21 January 2018

1 reference

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.10.41

1 reference

22 August 2017

1 reference

PubMed ID

20465381